insitro, South San Francisco, CA, Hybrid
insitro's mission is to bring better drugs faster to patients who can benefit most, through machine learning and data at scale. Our discovery strategy integrates insights from multiple phenotypic readouts across diverse high-content data modalities, including data from public and proprietary human cohorts and in vitro cellular systems generated by our proprietary, automated wet-lab platforms.
In this role, you will lead and grow a team of exceptional machine learning researchers responsible for co-developing methods for extracting information from in-vitro biology using computer vision and machine learning. You will lead an established team of 5 machine learning scientists, several at the Staff level, and be expected to grow it over time. Your team will partner closely with laboratory scientists to develop biological assays in a tight loop, iterating sample preparation protocols and feature extraction methods in tandem. As the manager of this team, you will be responsible for structuring these collaborations in ways that ensure the success of all teams, and your individual team members, as measured by our ability to drive insitro's therapeutic programs forward through understanding of causal human biology.
In addition to working closely with the lab, you and your team will partner closely with our imaging software team, responsible for co-developing and scaling methods your team develops, and computational biologists who will subsequently leverage these tools to extract program-level insights in conjunction with omics (perturb-seq) and clinical insights. As the leader of a team of researchers within the AI/ML organization, you will be expected to remain abreast of the evolving field of in-vitro screening. You will report to the Director of Imaging, Cellular Machine Learning. This is a hybrid position that requires you to be in our South San Francisco headquarters at least three days per week. Join us, and help make a difference to patients!
Our target starting salary for successful US-based applicants for this role is $247,000 - $262,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
Please be aware of recruitment scams: we never request payments, all recruitment communications are from @_[_insitro.com_](http://insitro.com) _, and if in doubt, contact us at_ __info@insitro.com__ _._
About insitroinsitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit [www.insitro.com](http://www.insitro.com).
Insitro is an AI-driven drug discovery and development company leveraging machine learning and large-scale biological data to create better medicines faster.
View company profile →